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Figure 2. Functional analysis of NF-M reveals trans-activating and inhibitory domains. [A] NF-M deletions were constructed in the 
pCDM8 expression vector and transfected into QT6 fibroblasts together with the M82 cMGF promoter-luciferase reporter as shown 
at the top. The reporter contained both its NF-M-binding sites, which are arranged as an inverted repeat (Sterneck et al. 1992b). 
Forty-eight hours after transfection, cell extracts were prepared, normalized, and analyzed for reporter and bandshift activity {lower] 
as described (Sterneck et al. 1992a,b). (5) A modified version of the cMGF promoter containing 4x Gal4-binding sites replacing the 
NF-M-binding sites as indicated was transfected and analyzed as described above. The data represent means of triplicates; standard 
deviations were within the 10% range. Nuclear extracts were examined as in A. 
several amino-terminal CRs contribute to the trans-ac-
tivating function of the protein (a comprehensive analy­
sis of the trflns-activation region of NF-M w i^ll be pub­
lished elsewhere). In contrast, internal deletion of amino 
acids 116-229 (CRS, CR6, and CR7) enhanced the trans-
activation five- to sevenfold in comparison to full-length 
NF-M (FLNF-M). Thus, the region between amino acids 
116 and 229 partially represses the activity of NF-M. 
Internal deletions within this region enabled a more de­
tailed analysis of this possibility (Fig. 2A). Removal of 
CRS or CR7 alone or in combination enhanced reporter 
expression five- to sevenfold over FLNF-M. Likewise, ad­
dition of CRS or CR7 to a construct consisting of the 
trcms-activating domain (CR1-CR4; amino acids 1-113) 
diminished reporter activity to wild-type level. Hence, 
two motifs, CRS and CR7, repress the full trans-activa­
tion potential of NF-M. In contrast, CR6 appeared to 
partially antagonize the inhibitory effects of CRS or CR7 
because its deletion (ACR6) strongly reduced reporter ex­
pression, whereas its presence masks the negative effect 
of either single inhibitory region CRS or CR7 alone (as in 
the constructs ACRS and ACR7). Among other possibil­
ities, it is tempting to speculate that CR6 is required to 
maintain a conformational state that is crucial for NF-M 
derepression. 
Are the trans-activation and inhibitory domains inde­
pendent modules of NF-M or are they intrinsically de­
pendent on the carboxy-terminal portion of the protein? 
To address this question we exchanged the carboxy-ter­
minal 96 amino acids of NF-M for the DNA-binding 
dimerization domain of the yeast transcription factor 
Gal4 [Gal4( 1-147)] (Ptashne 1988; Sadowski and Ptashne 
1989). Transient reporter expression (Fig. 2B) revealed 
that activatory and inhibitory domains functioned in a 
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similar way as in the original mutants. These results 
indicated that neither the activating nor the repressing 
hmctions of NF-M depended on the native DNA-binding 
or dimerization domains. 
Reporter assays however do not prove conclusively 
that the inhibitory and activating domains of NF-M have 
similar functions on endogenous genes. Transient ex­
pression of NF-M alone is sufficient to activate a panel of 
myelomonocytic-specific genes in unrelated cell types 
(E. Kowenz-Leutz and A. Leutz, in prep.). This enabled us 
to examine whether the repression mediated by the in­
hibitory regions within amino acids 116-229 was also 
applicable to chromatin-embedded genes (see Fig. 3). Un­
der normal conditions, fibroblasts do not express RNA 
for gene 126 [encoding a potential Ca^"^-binding protein 
that is specifically expressed in myelomonocytic cells 
(Nakano and Graf 1992)]. Transfection of the FLNF-M 
expression vector into QT6 fibroblasts already caused a 
weak induction of the 126 message. Here, too, removal 
of the inhibitory regions strongly enhanced 126 expres­
sion. Taken together, our data suggest that inhibitory 
functions within NF-M conceal its potential to activate 
reporter and resident genes. 
Inhibition of NF-M is negatively regulated by kinase 
oncogenes 
The fact that in fibroblasts NF-M is partially repressed 
suggests that its normal mode of activation in cells may 
be through derepression. Trans-activation of NF-M/C/ 
EBPp is enhanced by a calcium ionophore, phorbol ester 
treatment, bacterial lipopolysaccharide (LPS), by ras, or 
by various kinase oncogenes as found by us and other 
workers (Akira et al. 1990; Stemeck et al. 1992b; Wegner 
et al. 1992; Nakajima et al. 1993; Trautwein et al. 1993). 
Furthermore, activation of mammalian C/EBP(i by phor­
bol esters or oncogenic ras coincides with increase of 
.^"^  4' ^ ^ 
a- CJ 
#126 
GAPDH 
Figure 3. Inhibitory regions of NF-M conceal its ability to ac­
tivate chromatin-embedded genes. Expression plasmids as indi­
cated at the top were transfected in QT6 fibroblasts. After 36 hr, 
cells were lysed and their poly(A) "^  fraction examined by North-
em analysis with #126 and GAPDH probes. 
phosphorylation at positions that are within inhibitory 
motifs CR5 and CR7 (Nakajima et al. 1993; Trautwein et 
al. 1993). To investigate whether an oncogenic receptor 
tyrosine kinase can enhance NF-M activity by neutral­
izing its inhibitory regions, we took advantage of an ery-
throid cell line (HD3) that harbors a temperature-sensi­
tive version [ts] of the v-erbB oncogene (Graf et al. 1978; 
Beug et al. 1982). In contrast to QT6 fibroblasts, ectopi-
cally expressed FLNF-M induces #126 expression to a 
similar level as ACR7 in HD3 cells (Fig. 4A). This indi­
cates that in HD3 cells, FLNF-M is already activated at 
the permissive temperature. That the activity of NF-M 
was dependent on the v-erbB kinase was confirmed by 
the finding that at the nonpermissive temperature where 
the conditional tsv-erbB kinase is inactivated (Beug and 
Hayman 1984), the expression of #126 by FLNF-M was 
completely abrogated. Importantly, both ACR5 or ACR7 
induced #126 expression even in the absence of func­
tional tsv-erbB. These results imply that tsv-erbB over­
comes the inhibition of FLNF-M at the permissive tem­
perature and that removal of the inhibitory regions cir­
cumvents the requirement for the kinase at the 
nonpermissive temperature. The observed differences 
were not the result of the particular gene (#126) exam­
ined, because another myelomonocyte-specific gene, 
#325 [encoding the chicken homolog of the granulocyte-
specific goose-type lysozyme (Nakano and Graf 1992)], 
was activated in a similar fashion (Fig. 4A). Furthermore, 
protein levels were comparible between the wild-type 
and mutant proteins even at the nonpermissive temper­
ature (Fig. 4B). Therefore, the differences were not be­
cause of altered mutant protein expression, intracellular 
localization, or changes in the ability of mutant proteins 
to bind to DNA, respectively, as shown by the controls 
(Fig. 4B,C). 
We then examined whether or not kinase-induced ac­
tivation of NF-M was dependent on protein synthesis. 
To do so, tsv-erbB kinase was reactivated by backshif ting 
to the permissive temperature in the presence of cyclo-
heximide as indicated in Figure 5. Under these condi­
tions, tsv-erbB kinase induced #325 expression even 
when protein synthesis was blocked. These results sug­
gest that the inhibitory function is mitigated by tsv-erbB 
or downstream mediators through a post-translational 
mechanism. 
Finally, we asked whether oncogenes that act down­
stream of or in parallel to v-erbB in the signaling cascade 
can rescue FLNF-M activity. We transfected HD3 cells 
with expression vectors encoding E]-ras, v-mil, or PMT 
oncogenes and incubated the cells at the nonpermissive 
temperature to inactivate the tsv-erbB kinase as shown 
in Figure 6a. In the presence of FLNF-M, each of the 
signaling oncogenes at least partially induced the resi­
dent #126 gene or #325 gene (data not shown) and thus 
complemented the inactive v-erbB kinase. In the absence 
of NF-M, none of the signaling oncogenes examined 
were capable of inducing #126 or #325 (data not shown; 
Fig. 6B). To rule out cell lineage-specific effects, we 
asked whether induction of the signaling cascade in fi­
broblasts could also activate NF-M. Figure 6B shows that 
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Figure 4. Trans-activation by NF-M depends on an activated 
receptor tyrosine kinase or removal of inhibitory regions. [A] 
HD3 cells harboring the conditional tsv-erbB oncogene (Beug 
and Hayman 1984) were transfected with expression constructs 
as indicated (cf. with Fig. 2a) and incubated for 24 hr at the 
permissive temperature (+, 36°C) or the nonpermissive temper­
ature {-, 42°C, the normal body temperature of chicken). Acti­
vation of resident NF-M target genes and GAPDH controls were 
monitored by Northern analysis. [B] Total cellular protein ex­
tracts were prepared in parallel, equivalents of 5 x 10^ cells were 
subjected to SDS-gel electrophoresis, blotted, and probed with 
an NF-M antiserum. (C) Nuclear protein extracts were prepared 
in parallel and examined for DNA binding by bandshift analysis 
as described (Stemeck et al. 1992b). NF-M shifts were controlled 
by competition analysis with a 100-fold excess of unlabeled 
oligonucleotide (oligo comp.) and supershift (+ aS) using a 1:500 
dilution of a specific NF-M antiserum (Katz et al. 1993). 
coexpression of PMT together with NF-M induced #126 
expression to a similar level as ACR7, whereas the ac­
tivity of ACR7 was not further increased by PMT. PMT 
on its own did not induce #126 at all, confirming that 
trans-activation occurs through NF-M. 
If phosphorylation of the inhibitory motifs is respon­
sible for activation of NF-M, their removal should be 
accompanied by a reduction in phosphorylation of the 
mutant molecules. To examine this possibility, we com­
pared specific phosphorylation levels of transiently ex­
pressed NF-M derivatives following metabolic labeling 
of HD3 cells as shown in Figure 7. To do so, NF-M con­
structs were modified to encode the FLAG-tag epitope at 
their carboxyl teminus to ensure equal antigenicity of 
the constructs. These constructs were then transfected 
into HD3 cells that were subsequently metabolically la­
beled with radioactive inorganic phosphate, lysed, im-
munoprecipitated with a FLAG-specific monoclonal an­
tibody, and the ^^P label was quantified by Phosphorlm-
age analysis. To determine specific ^^P incorporation 
into wild-type and mutant proteins quantitatively, the 
same blot was incubated with anti-FLAG followed by an 
antimouse ^^^I Fab fragment and subsequently analyzed 
as above. The ratio of ^^P to ^^^I label in wild-type NF-M 
was set to 1.0 and plotted as shown in Figure 7. Deletion 
of CR5, CR7, or both together diminished specific phos­
phate incorporation to 50%, 10%, and 5%, respectively. 
Thus, the inhibitory regions CR5 and CR7 provide the 
majority of phosphorylation sites in NF-M. It also ap­
pears that phosphorylation of CR5 and CR7 may to some 
extent be interdependent on each other. Importantly, ^^P 
incorporation was lowest in mutants with highest gene 
activation potential. It therefore appears that phospho-
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Figure 5. Kinase-mediated NF-M activation occurs indepen­
dently of protein synthesis. HD3 cells were transfected with the 
constructs as indicated at left and #325 expression was ana­
lyzed 16 hr after transfection. Indicated is the time course of 
incubation temperatures, the state of activity of the tsv-erfc>B 
kinase (+, active; - , inactive), and the addition of cyclohexi-
mide by an arrow. Briefly, following transfection, cells were 
incubated at the nonpermissive temperature (with exception of 
one of the vector controls) for 16 hr or backshifted after 12 hr to 
the permissive temperature for 4 hr. Where indicated by an 
arrow, cycloheximide (at 50 p-g/ml) was added 20 min before 
back shift to block protein synthesis. Northern blots were eval­
uated quantitatively by Phosphorlmage analysis (BaslOOO, Fuji) 
and normalized to the GAPDH control, and #325 expression 
induced by ACR7 was set to 1.0 (arbitrary units). 
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Figure 6. Deinhibition of NF-M occurs by signaling onco­
genes. [A] Complementation of conditional tsv-eibB in HD3 
erythroblasts. HD3 cells were transfected with expression con­
structs encoding NF-M derivatives, EJ-ras, v-mil (chicken laf 
oncogene), or PMT, as indicated, incubated at the permissive or 
nonpermissive temperature for 24 hr, and harvested; and the 
polylA)"^ RNA fraction was analyzed by Northern blotting us­
ing #126 and GAPDH probes. (B) QT6 fibroblasts were trans­
fected with expression constructs as indicated; and the level of 
resident #126 gene expression was evaluated quantitatively by 
Phosphorlmaging analysis following Northern hybridization. 
rylation of the inhibitory regions abolishes their ability 
to suppress trans-activation. 
It appeared unlikely that the v-erbB kinase directly 
phosphorylates NF-M, as we failed to detect phosphory-
lated tyrosine residues on NF-M foUow^ing metabolic la­
beling of HD3 cells (data not shown). On the other hand, 
we had pointed out previously that a consensus sequence 
for MAPK within CR7 (Pro-Gly-Thr-Pro) is conserved 
between avian and mammalian C/EBPp (Katz et al. 
1993). Subsequently, a peptide from NF-IL6 (human 
C/EBPp) comprising this site was shovm to be phospho-
rylated by purified MAPK and to be a target for the las 
oncogene in P19 cells (Nakajima et al. 1993). Hence, we 
examined whether a point mutation at this site (thr218 
to asp218) could also derepress NF-M. Figure 7B shows 
that mutation of the MAPK target in NF-M218D miti­
gated the requirement for v-erbB to activate the resident 
#126 and #325 genes. Thus, the inhibitory function 
could be overcome either by deletion of repressing re­
gions, activation of signaling oncogenes, or by a point 
mutation at a MAPK phosphorylation site within the 
inhibitory CR7. 
Inhibitoiy and tians-activating regions of NF-M 
interact 
We decided to probe the mechanism by which NF-M 
inhibition is accomplished using the yeast "two-hybrid" 
interaction trap system. This approach allowed us to as­
certain whether the inhibitory regions interact with the 
trans-activating region. To do so, we cloned various parts 
of NF-M into yeast expression vector pairs that express 
the peptides of interest as fusion proteins (Fields and 
Song 1989). Here, blue colonies appear on X-gal plates 
when two protein sequences interact to induce galactosi-
dase expression. As shown in Table 1, we found that the 
trans-activating region CR1234 of NF-M (cloned into the 
activation hybrid vector, pGAD424) induced galactosi-
dase activity when cotransf erred with either CR5 or CR7 
(cloned into the DNA-binding hybrid pGBT9). Moreover, 
CR7 domains can be seen to interact with each other 
imder these conditions, an observation that is discussed 
later in this paper. The kinetics of color appearance in 
these experiments was similar to the color development 
observed in the positive control as shown in Table 1 (p53 
protein interaction with SV40 large T antigen). Likewise, 
we examined the effect of the point mutation at amino 
acid 218 in the MAPK site. As shown in Table 1, 
CR7D218, which harbored the T218 to D218 mutation, 
was completely impaired in its interaction with CR1234. 
This was not because of the failure to express this mu­
tant, because it still retained the ability to interact with 
CR7, as shov^m in the table. These results suggest that 
the inhibitory regions interact wi th the trans-activating 
B 
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Figure 7. In vivo-labeling of NF-M mutants and mutagenesis 
of a critical phosphorylation site. {A] Specific phosphate con­
tents of various NF-M constructs. To obtain equal antigenicity, 
NF-M constructs were tagged with the FLAG peptide (tg) fused 
in-frame to their carboxyl termini. These constructs were trans­
fected into HD3 cells. After 16 hr, cells were labeled with 
[^^Pjorthophosphate for 4 hr, lysed, and immunoprecipitated 
(Trautwein et al. 1993) with monoclonal anti-FLAG antibody, 
separated by SDS-PAGE, blotted to PVDF membrane, exposed 
to reveal ^^P label, and quantitatively evaluated by Phosphorlm-
age analysis. To determine protein levels, the blot was subse­
quently incubated with anti-FLAG antibody followed by ^^ I^-
labeled second antibody and quantitatively analyzed as above. 
The ratio between ^^ P label (phosphate incorporation) and ^^ I^ 
label (protein level) was calculated, normalized to 1.0 for FLNF-
M, and plotted as shown. [B] HD3 erythroblasts were trans­
fected with expression constructs encoding NF-M derivatives, 
incubated for 20 hr under permissive or nonpermissive condi­
tions as shown, and analyzed for RNA expression by Northern 
analysis. NF-M218D is a derivative of the full-length protein, 
where threonine 218 was replaced with aspartic acid by site-
directed mutagenesis. 
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Table 1. Interaction between hybrid proteins in yeast 
DNA-binding hybrid 
(in pGBT9) 
GalDBD 
GalDBD-p53'' 
GalDBD-p53 
GalDBD-p53 
GalDBD 
GalDBr>-CR5 
GalDBD-CR5 
GalDBD-CR7 
GalDBD-CR7 
GalDBD-CR7D2l8 
GalDBD-CR7D218 
GalDBD-CR7 
G31DBD-CR7D218 
GalDBD 
Trarzs-activation hybrid 
(in pGAD424) 
GalAD 
GalAD 
GalAD-CR1234 
GalAD-SV401argeT^ 
GalAD-CR1234 
GalAD 
GalAD-CR1234 
GalAD 
GalAD-CR1234 
GalAD 
GalAD-CR1234 
GalAD-CR7 
GalAD-CR7 
GalAD-CR7 
Color of 
colonies* 
white 
white 
white 
blue 
white 
white 
blue 
white 
blue 
white 
white 
blue 
blue 
white 
*The number of colonies per plate was in the range of 50-250. 
''Murine p53 amino acids 72-390. 
'=SV40 largeT amino acids 84-708. 
region probably by masking its activation potential. The 
finding that interaction of CR7 with the tians-activating 
domain can be abrogated by mutation in the MAPK site 
lends support to the idea that deinhibition of NF-M oc­
curs by kinase-induced unmasking of its trans-activation 
domain. Such a hypothetical mechanism is schemati­
cally shown in the model presented in Figure 8. 
Discussion 
Our data strongly favor a novel mechanism to control 
the activity of C/EBP^. We suggest that activation of 
signaling pathways results in phosphorylation of the in­
hibitory domains of C/EBPp, thereby eradicating the in­
hibition by exposing its trans-activating functions. 
Therefore, inactivation of inhibitory functions (negative 
regulation) rather than enhancement of the trans-activa­
tion domain (positive regulation) appears to be a major 
driving force of C/EBPp-induced gene transcription. 
The results obtained with reporter assays on defined 
promoter constructs demonstrate that activation of gene 
expression by deinhibition maps to the cis-regulatory el­
ements known to bind NF-M or its derivatives. How­
ever, replacement of the carboxy-terminal one-third of 
the protein (containing the b-Zip motif and DNA-bind­
ing domain) with the DNA-binding domain of the yeast 
trans-activator Gal4 creates a fusion protein that could 
still be activated by the same deinhibition mechanism as 
the wild-type protein. This suggests that the highly con­
served DBD-LZ region of NF-M is not essential for the 
activation mechanism. It does, however, not exclude 
that the DBD-LZ region participates in the regulation of 
NF-M/C/EBPp or the activation of some genes, for ex­
ample, in a cell type-dependent fashion as observed by 
others (Wegner et al. 1992). 
We provide evidence that two inhibitory domains, 
CR5 and CR7, interact with the trans-activation domain 
of NF-M and silence its function. One of the pathways to 
activate C/EBPp occurs through MAPKs that phospho-
rylate a highly conserved site in CR7 (Nakajima et al. 
1993). We demonstrate that activation is achieved by 
deletion of the entire region that harbors the MAPK site 
or by a point mutation at the MAPK site that mimics the 
negative charge of a phosphate residue. Along these 
lines, a mutation that inhibits phosphorylation of the 
homologous site in NF-IL6 was shown by others to result 
in loss of activation by the ras oncogene (Nakajima et al. 
1993). However, data presented in Figure 7A as well as 
peptide maps of in vivo-labeled NF-M mutants (data not 
shown) or human C/EBPp (Nakajima et al. 1993) indi­
cated several additional phosphorylation sites in the in­
hibitory regions with unknown function. At the mo­
ment we do not know the biological significance of these 
sites. However, the results obtained with the two-hybrid 
system indicates that the MAPK site is indeed a critical 
target of region CR7, because its mutation abrogates its 
interaction with the trans-activating domain of NF-M 
but not with CR7. The observation that the CR7 inhib­
itory regions interact with each other in the two-hybrid 
system also deserves attention. The major implication 
from this finding is that inhibition/activation may also 
be achieved by intermolecular interactions between 
NF-M molecules, as opposed to the intramolecular 
mechanism proposed for CR5 and CR7. Because NF-M/ 
C/EBPp readily forms heterodimers with other members 
of the C/EBP family, it will be interesting to investigate 
whether CR7 could also inhibit activation in trans. It 
would probably also help in understanding the function 
of the natural dominant-negative C/EBPp that is trans­
lated from an internal start codon at the beginning of 
CR7 by a ribosomal scanning mechanism (Descombes 
and Schibler 1991). 
The mechanism that targets the other inhibitory re­
gion, CR5, is less clear. Interestingly, PKC was suggested 
to mediate enhanced transcriptional efficacy through 
phosphorylation of a serine residue (Ser-105) in the rat 
C/EBP(3 version (Trautwein et al. 1993). According to 
our amino acid alignment of C/EBP proteins (Katz et al. 
1993), the equivalent position of rat C/EBPp SerlOS 
would be at the amino-terminal border of CR5. There­
fore, it appears that the apparent activation of rat 
C/EBPp may also be occurring through disruption of 
CR5. However, this particular phosphorylation site in 
the rat protein is conserved neither in human nor in 
chicken C/EBPp (Katz et al. 1993). It therefore appears 
possible that multiple ways exist to inactivate the inhib­
itory regions of C/EBPp. Like rat and human C/EBP(3, 
Inactive Active 
Figure 8. Predicted model of C/EBP(3 activation. 
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we also observe activation of NF-M by phorbol ester or 
LPS treatment. However, activation through both path­
ways is cell type-dependent. In myeloblasts that express 
large amounts of NF-M, neither LPS nor phorbol ester 
activate the NF-M-dependent cMGF promoter. On dif­
ferentiation of myeloblasts into macrophages, however, 
NF-M-dependent cMGF expression and cMGF promoter 
activity is mediated by phorbol ester or LPS through the 
NF-M-binding sites (Beug et al. 1984). In contrast, kinase 
oncogenes activate the cMGF promoter through its 
NF-M sites irrespective of the differentiation status of 
myelomonocytic cells (Adkins et al. 1984; Graf et al. 
1986; Stemeck et al. 1992a,b). This suggests that at least 
some of the pathways that mediate NF-M activation in 
myelomonocytic cells are sensitive to a differentiation 
program. Taken together, our data suggest that two re­
gions within NF-M, CR5, and CR7 mask the trans-acti­
vation domain and prevent its interaction with the basic 
transcription machinery. 
Many of the above data were obtained by exploiting 
the ability of NF-M to activate endogenous, chromatin-
embedded target genes and by using the ability of a con­
ditional oncogene to regulate the activity of NF-M. 
These experiments confirm the relevance of the deinhi-
bition mechanism in vivo. Modulation of NF-M activity 
and, in particular, its ability to regulate resident genes is 
somewhat reminiscent of the myogenic helix-loop-he­
lix proteins, where removing negative regulation of a sin­
gle transcription factor can override constraints in the 
activation of cell lineage-specific genes (Weintraub 
1993). Why is the trans-activation function of NF-M reg­
ulated by deinhibition? One advantage of this type of 
activation is that it could be achieved easily by many 
different means. They only need to have in common the 
ability to inactivate a specific protein function rather 
than to install one as it is the case with positive control 
mechanisms. We therefore anticipate that a range of sig­
naling pathways, effector molecules, and protein-pro­
tein interactions might converge on the inhibitory re­
gions of NF-M/C/EBPp. Conceivably, a model approxi­
mating this mechanism is shown in Figure 8 and might 
involve neutralization of the inhibitory domain causing 
a structural change that in turn reveals the previously 
concealed activation domain. Of course, more complex 
mechanisms involving dimerization partners or ancil­
lary proteins may also be possible and will be examined. 
The derepression mechanism described in this paper 
provides an explanation why the cMGF gene (which con­
tains binding sites for NF-M but not for Myb) becomes 
transcribed only after activation of oncogenic kinases in 
myelomonocytic cells that contain high amounts of 
NF-M (Stemeck et al. 1992a,b). In contrast, the mim-\ 
gene (which contains binding sites for both NF-M and 
Myb) becomes cooperatively activated by NF-M plus 
Myb in cells lacking an oncogenic kinase. How can this 
discrepancy be resolved? It is conceivable that on pro­
moters that contain adjacent cis-acting elements for 
both NF-M and Myb, derepression might occur through 
interaction with adjacently bound Myb, omitting the ki­
nase activation step. Activation of NF-M in this instance 
may occur through modulation of the same inhibitory 
regions by interaction with Myb. As mentioned earlier, 
it is possible that the local activation of NF-M by tran­
scription factors binding to neighboring sites determines 
the cell type-restricted transcriptional activity of NF-M 
and other C/EBPs. The requirement of accessory tran­
scription factor NF-Y in the case of C/EBPa-regulated 
albumin promoter activation has already been shown 
and supports this idea. Whether such a combinatorial 
site-restricted activation mechanism occurs between 
NF-M and Myb as well as how NF-M participates in 
v-myi>-induced transformation are currently under in­
vestigation. 
Materials and methods 
Plasmid constructions 
Expression plasmids were based on pCDM8 and maintained in 
the bacterial strain MC1061/P3 (Invitrogen). DNA cloning, re­
striction analysis, and sequencing were performed according to 
standard procedures (Ausubel et al. 1987; Sambrook et al. 1989). 
NF-M mutants and chimeric proteins were constructed by PCR 
approaches and sequenced following subcloning into pCDM8. 
NF-M constructs harboring their native DNA-binding and 
dimerization domains were generated from a 3' primer (BX) con­
taining BamHl and Xbal cleavage sites. To construct NF-M 5' 
deletion mutants, the following 5' primers were obtained as 
synthetic oligonucleotides: NF-M HEN, GCAAGCTTGAAT-
TCACCATGGAACGCCTGGTGGCCTGG; NF-MBX, GCTC-
TAGAGTGGATCCGCGCAGCGGGGCGAGGAAGCGAG; 
5D43, CGGAATTCAAGCTTACCATGGCGGCCGGGGGC-
CGCTCC; 5D83, CGGAATTCAAGCTTACCATGGCAGCA-
GCAGCAGGGGGC; 5D141, CGGAATTCAAGCTTACCAT-
GGGGGTGCTGCCGGGCTGC; 5D184, CGGAATTCAAG-
CTTACCATGGCCTCGCCCTACGGCAGC; 5D229, CGGA-
ATTCAAGCTTACCATGGCCGCCGGCGCCGGGGGC. All 
5' primers provide optimized translation initiation sequences 
(Kozak 1984) and convenient restriction sites to ease subclon­
ing. 
Mutant constructions were done as follows: To 100 ng of 
linearized plasmid encoding wild-type NF-M, 100 pmoles of the 
respective primer pairs was added and cycled through eight 
rounds of PCR amplifications, cut with HindUl-Xbal, separated 
by agarose gel electrophoresis, and cloned into pCDM8. Internal 
deletions were constructed by choosing appropriate primer pairs 
between Pro-Gly residues in the intervening, nonconserved 
parts of NF-M as indicated in Figure 1. The internal deletion 
primers harbored Smal-Xmal sites encoding Pro-Gly at the de­
letion endpoints and were used to amplify the respective parts 
of NF-M as described above. The following primers were used 
to construct intemal deletions: ID881, ATCCCGGGGAGT-
CCTCCAAGTCGGCC; ID747, TACCCGGGCCCCGCTCC-
CCCTTCTTC; ID743, ATCCCGGGCCAGGACCGGGGGG-
CATG; ID645, TACCCGGGCAGCACCCCCGGCTTGTG; 
ID633, ATCCCGGGGTGCTGCCGGGCTGCTTC; ID561, 
TACCCGGGGCCGCCGCTGCCTTTATA. After amphfica-
tion, products were cut with Hindlll-Xmal and Xmal-Xbal, 
respectively, purified by DNA-agarose gel electrophoresis and 
joined by three-factor ligation into pCDM8. By a similar strat­
egy, the translation initiation and multiple cloning site of Gal4 
(1-147) in the plasmid pSG424 (Sadowski and Ptashne 1989) 
were modified to a Nail site (which was in-frame with the 
NF-M Narl site) at the 5' end and an Xbal-translation stop 
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codon at the 3' end (5' primer sequence: GAL4DBSEH, GCAC-
TAGTGAATTCAAGCTTACCATGGCGCTACTGTCTTCT; 
3' primer sequence, GAL4DBBXC, GCATCGATCTAGAGTG-
GATCCGATACAGTCAACTGTCT). Appropriate NF-M con­
structs were ligated as Hindlll-Nail fragments to the modified 
Gal4DBD. Point mutation of the NF-M MAPK site was 
achieved with the primer NF-MBX and 
NF-M218D, CTCCGACCCCCCCGGCACCCCGAACCCC-
TCCGAGTCCTC. Amphfication from wtNF-M template was 
performed as described above. The PCR product was digested 
with Bgll and Xbal and ligated to the Hindlll-Bgll fragment of 
WtNF-M in pCDM8. This exchanged the threonine at position 
218 to aspartic acid. 
Two-hybiid system 
The two-hybrid system, yeast strains, and hybrid plasmids 
pGBT9 and pGAD424 were purchased from Clonetech. Gal4-
NFM chimeric proteins were constructed in two steps: NF-M 
fragments were first obtained by PCR and subsequently sub-
cloned in-frame to Gal4 sequences as described above. The fol­
lowing primers were obtained as synthetic oligonucleotides and 
used to construct the fragments containing CR1234 (primers IF 
and 4R), CR5 (primers 5F and 5R), CR7 (primers 7F and 7R), 
CR89 (primers 8F and 9R): IF, GCGAATTCCCCGGGATGC-
AACGCCTGGTGGCC; 4R, GCGGATCCGCCGCCGCCGC-
TGCCTTTATAGTC; 5F, GCGAATTCCCCGGGGGCGGC-
AAGAAGCCCGACTAC; 5R, GCGGATCCCAGCACCCCC-
GGCTTGTGGCTCTG; 7F, GCGAATTCCCCGGGGGCAT-
GTCCTCGCCCTAC; 7R, GCGGATCCTCACGGCCCCGA-
GTAGCCCCCGGC; 8F, GCGAATTCCCCGGGGCCGCCG-
GCGCCGGGGGCTAC; 9R, GCGGATCCTCAGCAGCGG-
GGCGAGGAAGCGAGCAG. All primers contain £coRI or 
BamHl restriction sites in-frame with the Gal moiety and clon­
ing sites of the vectors. After PCR amplification, fragments 
were cut with £coRI and BamHl, separated by agarose gel elec­
trophoresis, and ligated into appropriate vectors. Maxi-plasmid 
preparations were sequenced. All the experiments were per­
formed as described in the Clontech kit, except that plasmids 
were transformed by the method developed by Gietz et al. (1992) 
using the yeast strain SFY526. Coloration of filter-transferred 
and lysed yeast colonies was analyzed in all cases after 6 hr at 
30°C of incubation with lacZ buffer containing 0.35 mg/ml of 
X-gal. The ability of p53 to interact with large T was used as 
positive control, which was provided with the Clonetech kit. 
All experiments were repeated at least three times with identi­
cal results. 
Cell culture, tiansfection, metabolic labeling, and 
imm unopiecipi tation 
The quail fibroblast cell line QT6 and the chicken HD3 (eryth-
roblast) line have been described (Beug et al. 1979). All cells 
were grown in Dulbecco's modified Eagle medium (DMEM) 
supplemented with 8% fetal calf serum, 2% heat-inactivated 
chicken serum, 10 mM HEPES-NaOH (pH 7.2) plus penicillin, 
and streptomycin in a humidified incubator in 5% CO2 at 36°C. 
Temperature shifts were done by incubating cells at 42.5°C to 
inactivate the tsv-ezbB kinase. Cells were harvested 14—24 hr 
after the temperature shift. Backshift experiments were per­
formed by incubating the cells for 12 hr at the nonpermissive 
temperature (42.5°C) followed by incubation for 4 hr at the per­
missive temperature (36°C). Where indicated, cycloheximide 
(50 |xg/ml) was added 20 min before back shift to block protein 
synthesis. The transfection procedures using DEAE-dextran 
have been published in detail (Katz et al. 1993; Stemeck et al. 
1992a,b). Briefly, for reporter assays, 2x10*^ cells were trans-
fected for 30-45 min at 36°C with 200 ng of expression vector 
and 1 |jLg of reporter plasmid in 0.3 mg/ml of DEAE-dextran 
(Sigma) in STBS solution (Ausubel et al. 1987). Cells were pel­
leted, seeded in 4 ml of tissue culture medium, and harvested 
after 48 hr. For Northern analysis, transfection protocols and 
cell number were scaled up 10-fold. COS-7 cells were trans-
fected with lipofectin (GIBCO-BRL) according to the manufac­
turer's instructions at 3x10^ cells in 60-mm tissue culture 
dishes and harvested after 3 days. Twelve hours after transfec­
tion, metabolic labeling with [^^Pjorthophosphate was per­
formed for 4 hr. Cells were washed three times in phosphate-
free DMEM (Sigma) and incubated with 0.5-1 mCi/ml of 
P^Pjorthophosphate (5000 Ci/mmole) in phosphate-free DMEM 
supplemented with 10% dialyzed fetal calf serum. Cells were 
washed twice in TBS (25 mM Tris-HCl at pH 7.5, 150 mM NaCl, 
100 mM sodium orthovanadate, 1 mM DTTj and lysed in RIP A 
buffer (50 mM Tris at pH 8.0, 150 mM NaCl, 1% Triton X-100, 
1% sodium deoxycholate, 0.1% SDS, 10 mM DTT, 100 mM so­
dium orthovanadate, 10 mM aprotinin, 10 mM leupeptin). To 
equalize antigenicity of NF-M derivatives, the FLAG peptide 
(Kodak) tag was fused in-frame to the carboxyl terminus by the 
PCR method as described above. The sequence of the oligonu­
cleotide encoding the FLAG tag was DTKDDDDK. NF-M-
FLAG chimeras were immune-precipitated with anti-FLAG an­
tibodies (Kodak) and washed three times with RIPA buffer. '^ ^P-
Labeled immunoprecipitates were separated by SDS-PAGE, 
transferred to PVDF membranes (Millipore), and evaluated 
quantitatively by Phosphorlmage analysis (Fuji-Bas 1000). Fol­
lowing exposure to determine ^^ P contents, protein blots were 
blocked with dry-milk solution (6% in 25 mM Tris at pH 8.0, 
150 mM NaCl), and probed with anti-FLAG M2 monoclonal 
antibody (Kodak). Quantitative evaluation of NF-M constructs 
were performed with ^^^I-labeled second antibody and Phospho­
rlmage analysis. The ratio of ^^P to ^^^I-specific radioactivity 
was determined. 
Reportei and resident gene activation assays 
The cMGF reporter construct (M82) has been described (Ster-
neck et al. 1992b). The Gal4-responsive cMGF promoter was 
constructed by replacing the two NF-M-binding sites of the - 82 
cMGF promoter with four tandemerized binding sites for the 
Gal4 DBD. Transient expression assays, luciferase assays, and 
normalization were performed as described elsewhere (Stemeck 
et al. 1992a,b; Katz et al. 1993). 
To monitor endogenous gene activation, total RNA was ex­
tracted from transfected cells using a guanidinium-isothiocy-
anate method (Chomczynski and Sacchi 1987). The polyadenyl-
ated RNA fraction was isolated using magnetic oligo(dT) beads 
(Dynal) as recommended by the manufacturer. RNA was sepa­
rated on 1.2% formaldehyde-agarose gel electrophoresis and 
transferred by vacuum blotting to nylon membranes (Hybond, 
Amersham). Blots were probed in QuickHyb hybridization so­
lution (Stratagene) at 65°C for 2 hr with appropriate random 
^^P-labeled (Pharmacia, Amersham) DNA fragments as shown 
in Figures 3-7. Before exposure, filters were washed twice for 15 
min with 2x SSC, 0.1% SDS at room temperature and twice for 
15 min with 0.2 x SSC, 0.1% SDS at 60°C and exposed to Kodak 
XAR5 X-ray film or to Phosphorlmaging screens. Phosphorlm­
age and quantitation analysis was performed using the manu­
facturer's software packages (Fuji or Molecular Dynamics). For 
reprobing, filters were stripped in 0.04x SSC, 0.1% SDS at 95°C 
for 2 min. 
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Nuclear extracts and DNA-binding assays 
Nuclear extracts from HD3 or COS-7 cells were prepared as 
described by a mininuclear extract procedure (Schreiber et al. 
1989) in the presence of protease inhibitors. The double-
stranded oligonucleotide C/EBP-binding site (Ness et al. 1993) 
or Gal4-binding site was labeled with [a-'^ ^P]dCTP by end-filling 
with Klenow polymerase. Mobility shifts were performed ex­
actly as described previously (Stemeck et al. 1992b; Katz et al. 
1993). Where indicated, polyclonal rabbit antiserum raised 
against bacterially expressed NF-M was diluted with PBS (1:500 
final concentration) and added to the binding reaction 10 min 
after mixing nuclear extracts and DNA. Samples were incu­
bated on ice for an additional 10 min before electrophoresis. 
Electrophoresis was performed on 5% polyacrylamide gels in 
0.5 X TBE at 25 mA at room temperature. 
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